shareholdersunite.com

It’s only a relatively small player in the rapidly expanding field of genetic testing, but this is changing in front of our eyes. It was already known for the quality of their platform which could develop new tests faster than most and at lower price points. But what they have done with Covid testing is […]

[Read more →]

The company’s strong growth is likely to suffer as a result of the pandemic, but we think this is only a temporary blip. The company rapidly adjusted and developed two COVID-19 tests for which demand is now ramping rapidly, and demand for their other tests will resume growth near term. The cost of rolling out […]

[Read more →]

Fulgent’s growth is going to come down this year, according to guidance which was issued just before the coronavirus hit the US in earnest. From competitors with more recent updates, the picture doesn’t seem to be too alarming, at least not yet. Fulgent remains a solid growth company, and investors can nibble at the shares […]

[Read more →]

While it is very small relative to big competitors, it is growing much faster than the market, leading to margin expansion and operational leverage. Introducing new tests, a new consumer business, doing testing for others and international growth are some of the multiple growth avenues in front of the company. The company seems to have […]

[Read more →]

We think that after some consolidation of recent strong gains, shares of Fulgent Genetics have further upside. The market for genetic testing is still in the early innings, and the company has established itself as a genuine supplier. The company is on the verge of becoming profitable, and the shares are still not that expensive, […]

[Read more →]